GDOC:NYE-Goldman Sachs ETF Trust (USD)

ETF | Others |

Last Closing

USD 32.419

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

800.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund invests, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes (measured at the time of purchase) in equity investments in U.S. and non-U.S. health care companies. The adviser generally intends to invest in companies that the adviser believes are aligned with key themes associated with innovation in health care, which include, but are not limited to, genomics, precision medicine, technology-enabled procedures, and digital healthcare. The fund is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-17 )

ETFs Containing GDOC

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.87% 19% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.87% 9% A- 21% F
Trailing 12 Months  
Capital Gain 9.13% 45% F 45% F
Dividend Return 0.60% 8% B- 6% D-
Total Return 9.73% 35% F 35% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 2.56% 56% F 43% F
Dividend Return 2.56% 49% F 35% F
Total Return 0.00% 2% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 7.82% 64% D 85% B
Risk Adjusted Return 32.77% 47% F 49% F
Market Capitalization 0.02B 33% F 12% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.